

17 July 2024

Endometrial Cancer Treatments

Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments?

- Yes

Q2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments:

- Dostarlimab (Jemperli) <5
- Dostarlimab (Jemperli) AND Chemotherapy <5
- Hormone therapy (Progesterone or Letrozole) prescribed by GP
- Pembrolizumab (Keytruda) monotherapy <5
- Lenvatinib + Pembrolizumab (Lenvima +Keytruda) 5
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) N/A
- Any other SACT

Carboplatin AUC6	21
Cisplatin XRT	<5
Paclitaxel & Carboplatin	16

Q3. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy?

- Not available

Q4. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments:

- Dostarlimab (Jemperli) AND Chemotherapy <5
- Hormone therapy (Progesterone or Letrozole) prescribed by GP
- Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) N/A
- Any other SACT

Carboplatin AUC6	15
Cisplatin XRT	<5
Paclitaxel & Carboplatin	11

17 July 2024

Q5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part.

- One study open to patients with endometrial cancer – ‘Rare Neoplasms of Gynaecological Origin’ <5 patients

Please note:

We are unable to provide an exact figure where numbers are very low, <5. To provide this level of information would reduce numbers to discoverable limits where the patients could be identifiable. This is because many of these drugs are high cost and prescribed on a named patient basis. Pharmaceutical companies, would be aware of this.

This is exempt from release under section 40(2) Personal Information relating to a third party, of the FOI Act.

Disclosure would constitute a breach of the principles of the Data Protection Act 2018.